Search

Your search keyword '"ANTINEOPLASTIC AGENTS"' showing total 106,663 results
Start Over Descriptor "ANTINEOPLASTIC AGENTS" Topic business
106,663 results on '"ANTINEOPLASTIC AGENTS"'

1. Candel Therapeutics showcases cancer therapy candidates at IOVC

Subjects
Antineoplastic agents, Immunotherapy, Cancer -- Care and treatment, Antimitotic agents, Business, News, opinion and commentary
Abstract

Candel Therapeutics announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference, taking place October 27-30, 2024, in Rotterdam, the Netherlands. The presentations will showcase Candel's advancements in innovative [...]

Published
2024

2. Hutchmed withdraws NDA in China for fruquintinib in combination with paclitaxel

Subjects
Antineoplastic agents, Antimitotic agents, Business, News, opinion and commentary
Abstract

Hutchmed announced that it has voluntarily withdrawn its supplemental new drug application in China for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction [...]

Published
2024

3. Pfizer betting its future on cancer drugs, WSJ reports

Subjects
Pfizer Inc., Antineoplastic agents, Pharmaceutical industry, Antimitotic agents, Business, News, opinion and commentary
Abstract

Pfizer is betting much of its future on cancer drugs, believing they can earn billions of dollars in sales and turn around a company that has been struggling with falling [...]

Published
2024

4. C4 Therapeutics Inc To Host Preliminary Monotherapy Results Call - Final

Subjects
Pfizer Inc., Gene mutations, Antineoplastic agents, Pharmaceutical industry, Antimitotic agents, Business
Abstract

Presentation OPERATOR: Good day, and welcome to the preliminary monotherapy results from the ongoing Phase 1 trial of CFT1946 presented at ESMO conference call. (Operator Instructions) Please note this event [...]

Published
2024

5. AstraZeneca reports Truqap plus Faslodex approved in EU for breast cancer

Subjects
AstraZeneca PLC, Antineoplastic agents, Breast cancer -- Care and treatment, Pharmaceutical industry, Antimitotic agents, Business, News, opinion and commentary, European Union, Faslodex (Medication), Truqap (Medication)
Abstract

AstraZeneca's Truqap in combination with Faslodex has been approved in the European Union for the treatment of adult patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with [...]

Published
2024

6. Burning Rock Biotech enters collaboration with Bayer to develop cancer medicine

Subjects
Bayer AG, Antineoplastic agents, Biotechnology, Cancer -- Drug therapy, Pharmaceutical industry, Antimitotic agents, Business, News, opinion and commentary
Abstract

Burning Rock (BNR) has recently announced a collaboration with Bayer (BAYRY) to develop next-generation sequencing, or NGS-based companion diagnostic assays, or CDx, aiming to provide diagnostic methods, to enable treatment [...]

Published
2024

7. AstraZeneca reports Truqap plus Faslodex recommended for EU approval by CHMP

Subjects
AstraZeneca PLC, Antineoplastic agents, Clinical trials, Pharmaceutical industry, Antimitotic agents, Business, News, opinion and commentary, European Union, Faslodex (Medication), Truqap (Medication)
Abstract

AstraZeneca's Truqap in combination with Faslodex has been recommended for approval in the European Union for the treatment of adult patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast [...]

Published
2024

8. Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo[R] (nivolumab) plus Yervoy[R] (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Subjects
Bristol-Myers Squibb Co., Ono Pharmaceutical Company Ltd., Antineoplastic agents, Metastasis -- Care and treatment, Colorectal cancer -- Care and treatment, Immunotherapy, Cancer -- Genetic aspects -- Chemotherapy, Chemotherapy, Pharmaceutical industry, Antimitotic agents, Business, Business, international, Yervoy (Medication), Opdivo (Medication)
Abstract

Opinion based on results from the Phase 3 CheckMate -8HW trial, in which the dual immunotherapy combination of Opdivo and Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free [...]

Published
2024

9. AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN(TM) (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS

Subjects
United States. Food and Drug Administration, Patient compliance, Nilotinib, Antineoplastic agents, Drug approval, Antimitotic agents, Business, News, opinion and commentary, Tasigna (Medication)
Abstract

WOBURN, Mass., Nov. 14, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten[sup.(TM)], the first and only nilotinib with no mealtime [...]

Published
2024

10. Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Subjects
Antineoplastic agents, Immunotherapy, Hepatoma, Antimitotic agents, Business, News, opinion and commentary
Abstract

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4294446-1&h=945549291&u=https%3A%2F%2Fcarismatx.com%2F&a=Carisma+Therapeutics+Inc.(Nasdaq: https://c212.net/c/link/?t=0&l=en&o=4294446-1&h=1889052345&u=http%3A%2F%2Fwww.carismatx.com%2F&a=CARM) ('Carisma' or the 'Company'), a clinical-stage biopharmaceutical [...]

Published
2024

11. J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

Subjects
Yuhan Corp., Antineoplastic agents, Supercomputers, Medical colleges, Cancer, Antimitotic agents, Supercomputer, Business, News, opinion and commentary, National Assembly
Abstract

- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a pioneering collaboration in precision oncology. SEOUL, South Korea, Nov. [...]

Published
2024

12. Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Subjects
Antineoplastic agents, Chairpersons, Antimitotic agents, Business, News, opinion and commentary
Abstract

Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON, Nov. 4, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4293800-1&h=3972285224&u=https%3A%2F%2Fwww.moleculin.com%2F&a=Moleculin+Biotech%2C+Inc., (Nasdaq: MBRX) (Moleculin or the Company), a late [...]

Published
2024

13. BostonGene and Sarah Cannon Research Institute Collaborate to Accelerate the Development of Targeted Cancer Therapies and Improve Patient Outcomes

Subjects
Oncology, Experimental, Antineoplastic agents, Cancer patients -- Patient outcomes, Cancer -- Care and treatment -- Patient outcomes -- Research, Antimitotic agents, Research institutes, Business, Business, international
Abstract

WALTHAM, Mass. -- BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, and Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based [...]

Published
2024

14. Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA[R] (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG[R] (belzutifan) in Renal Cell Carcinoma

Subjects
Merck & Company Inc., Exelixis Inc., Antineoplastic agents, Biotechnology industry, Squamous cell carcinoma -- Development and progression, Pharmaceutical industry, Antimitotic agents, Business, Business, international, Keytruda (Medication)
Abstract

ALAMEDA, Calif. & RAHWAY, N.J. -- Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have [...]

Published
2024

15. ENHERTU[R] (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

Subjects
United States. Food and Drug Administration, Daiichi Sankyo Inc., AstraZeneca PLC, Antineoplastic agents, Metastasis -- Care and treatment, Patient compliance, Chemotherapy, Cancer -- Chemotherapy, Breast cancer -- Care and treatment, Pharmaceutical industry, Antimitotic agents, Business, Business, international, Enhertu (Medication)
Abstract

Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for ENHERTU If approved, AstraZeneca and Daiichi Sankyo's ENHERTU will be the first [...]

Published
2024

16. A Ray of Hope: An investigational breast cancer drug has been a game changer for one Central Florida patient

Author

Williams, Evan

Subjects
Antineoplastic agents, Chemotherapy, Cancer -- Chemotherapy, Breast cancer -- Drug therapy, Antimitotic agents, Business, Business, regional
Abstract

In an ongoing study, a new chemotherapy drug has shown success in treating patients with triple-negative breast cancer (TNBC), an unusually aggressive form of the disease. Janisette Rivera-Rollins is the [...]

Published
2024

17. Scandion Oncology A/S R&D Update - Final

Subjects
Antineoplastic agents, Antimitotic agents, Business
Abstract

Presentation MIKAEL MAGNUSSON, MODERATOR, DIREKT STUDIOS: The clock strikes 2:00 PM, and we are live here as Scandion Oncology joins us to give us some research and development update. And [...]

Published
2024

18. Olema Pharmaceuticals Inc Clinical Update - Final

Subjects
Antineoplastic agents, Antimitotic agents, Business
Abstract

Presentation OPERATOR: Good morning and welcome to the Olema Oncology webcast. (Operator Instructions) As a reminder, this conference is being recorded and a replay will be made available on the [...]

Published
2024

19. Moleculin Biotech Inc To Host AML Clinical Day - Final

Subjects
Antineoplastic agents, Biotechnology, Biotechnology industry, Antimitotic agents, Business
Abstract

Presentation JENENE THOMAS, INVESTOR RELATIONS, JTC TEAM, LLC: Okay, we are ready to get started. Welcome, everyone, to Moleculin Biotech's AML Clinical Day. My name is Jenene Thomas, and I [...]

Published
2024

20. Erasca reports Q4 EPS (20c), consensus (23c)

Subjects
Antineoplastic agents, Antimitotic agents, Company earnings/profit, Business, News, opinion and commentary
Abstract

Cash, cash equivalents, and marketable securities were $322M as of December 31, compared to $435.6M as of December 31, 2022.'...In 2023, our three clinical candidates reached important clinical and regulatory [...]

Published
2024

21. AstraZeneca's Truqap with Faslodex approved by Japanese MHLW

Subjects
AstraZeneca PLC, Antineoplastic agents, Pharmaceutical industry, Antimitotic agents, Business, News, opinion and commentary, Faslodex (Medication), Truqap (Medication)
Abstract

AstraZeneca's Truqap in combination with Faslodex has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast [...]

Published
2024

22. Findings from Center for Interdisciplinary Research Update Knowledge of siRNA-Based Therapy (Co-delivery of Doxorubicin and Vegf Sirna Using Carcinoembryonic Antigen-targeted Chitosan Nanoparticles for Colorectal Cancer)

Subjects
Endothelial growth factors, Antineoplastic agents, Colorectal cancer, Cancer -- Care and treatment, Interdisciplinary research, CEA (Oncology), Antimitotic agents, Business, Health, Health care industry
Abstract

2024 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Biotechnology - siRNA-Based Therapy. According to news reporting originating in [...]

Published
2024

23. 'Artificial Intelligence Guided Production of Cells and Organs from Pluripotent Stem Cells' in Patent Application Approval Process (USPTO 20240339176)

Subjects
Artificial intelligence, Antineoplastic agents, Stem cells, Antimitotic agents, Artificial intelligence, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- A patent application by the inventors Bartlett, Courtney (Niceville, FL, US); Ichim, Thomas (San [...]

Published
2024

24. Studies from Shanghai University Add New Findings in the Area of Cancer (A protracted war against cancer drug resistance)

Subjects
Oncology, Experimental, Antineoplastic agents, Drug resistance -- Drug therapy, Cancer -- Research, Antimitotic agents, Business, Health, Health care industry
Abstract

2024 OCT 15 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in cancer. According to news originating from Shanghai University by NewsRx [...]

Published
2024

25. Research from Texas Tech University Health Sciences Center Provide New Insights into Cancer (Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy)

Subjects
Oncology, Experimental, Antineoplastic agents, Drug resistance, Cancer -- Care and treatment -- Research, Antimitotic agents, Business, Health, Health care industry
Abstract

2024 OCT 15 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in cancer. According to news reporting out of Lubbock, Texas, by [...]

Published
2024

26. Cancervax, Inc. Files SEC Form 1-SA, (Sept. 30, 2024)

Subjects
United States. Securities and Exchange Commission, Biological products industry, Antineoplastic agents, Antimitotic agents, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 14 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

27. Alterome Raises $132M in Series B BIOPHARMA: Small Molecule Targeted Cancer Drugs

Author

Kastner, Jennifer

Subjects
The Goldman Sachs Group Inc. -- Officials and employees, Canaan Partners -- Officials and employees, Driehaus Capital Management Inc. -- Officials and employees, Biological products industry -- Officials and employees, Antineoplastic agents, Investment banks -- Officials and employees, Venture capital companies -- Officials and employees, Antimitotic agents, Business, Business, regional
Abstract

SAN DIEGO Biopharma startup Alterome Therapeutics landed a massive $132 million Series B deal led by Goldman Sachs Alternatives--a wing of global investment banking mega-corporation Goldman Sachs (NYSE: GS). Proceeds [...]

Published
2024

28. Avenzo Adds $150M to Series A Round BIOPHARMA: Funds to Fuel Breast Cancer Drug

Author

Kastner, Jennifer

Subjects
Biological products industry, Antineoplastic agents, Breast cancer, Periodical publishing, Antimitotic agents, Business, Business, regional
Abstract

SAN DIEGO--Carmel Valley clinical-stage biopharma startup Avenzo Therapeutics has secured an additional $150 million in an oversubscribed Series A round, bringing its total raised capital since its 2022 founding to [...]

Published
2024

29. Agents may bolster precision medicine in prostate cancer

Author

Seymour, Caroline

Subjects
Prostate cancer -- Drug therapy, Metastasis -- Drug therapy, Antineoplastic agents, Fludrocortisone, Antimitotic agents, Business, Health care industry
Abstract

In a recent presentation, Maha H.A. Hussain, MBChB, discussed 4 emerging pathways and agents that have the potential to bring an enhanced level of personalized medicine to the field of [...]

Published
2024

30. PARP inhibitors, imaging advances among recent prostate cancer highlights

Author

Mauro, Gina

Subjects
Prostate cancer, Antineoplastic agents, Antimitotic agents, Business, Health care industry
Abstract

Leonard G. Gomella, MD, FACS, hailed precision medicine's transformative influence on prostate cancer in a presentation during the New York GU[TM] 17th Annual Interdisciplinary Prostate Cancer Congress[R] and Other Genitourinary [...]

Published
2024

31. Working to Build Next-Generation Cancer Therapies

Subjects
Gilead Sciences Inc. -- Research -- Product development, Biological products industry -- Product development -- Research, Antineoplastic agents, Immunotherapy -- Research -- Product development, Cancer -- Care and treatment, Antimitotic agents, Business, Business, international
Abstract

M2 PRESSWIRE-September 19, 2024-: Working to Build Next-Generation Cancer Therapies (C)1994-2024 M2 COMMUNICATIONS RDATE:18092024 Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley [...]

Published
2024

32. Ten-Year Data for Merck's KEYTRUDA[R] (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma

Subjects
United States. Food and Drug Administration, Merck & Company Inc., Antineoplastic agents, Melanoma -- Patient outcomes -- Development and progression -- Care and treatment, Pharmaceutical industry, Antimitotic agents, Business, Business, international, Keytruda (Medication)
Abstract

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab RAHWAY, N.J. -- Merck [...]

Published
2024

33. Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo[R] plus Yervoy[R] in Advanced Melanoma

Subjects
Bristol-Myers Squibb Co., Ono Pharmaceutical Company Ltd., Antineoplastic agents, Melanoma -- Patient outcomes, Pharmaceutical industry, Antimitotic agents, Business, Business, international, Yervoy (Medication), Opdivo (Medication)
Abstract

These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) [...]

Published
2024

34. MacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Subjects
MacroGenics Inc., Oncology, Experimental, Patients -- Care and treatment, Antineoplastic agents, Class actions (Civil procedure), Stockholders' derivative actions, Cancer -- Research, Pharmaceutical industry, Antimitotic agents, Financial misrepresentations, Banking, finance and accounting industries, Business
Abstract

SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to https://www.globenewswire.com/Tracker?data=LJatbNxPhiYMi37MK0sw40mqmVwIemnfl6qtWJRMbtaoRbGqA9q8V8BX6uYu5VzKfGXONjmX4lpr13AB8PBfxRS2I2evYoZWP4ohdQ6HGx5HZSchz5Z_9zrElpb6p5lI. Class Period: Mar. 7, 2024 - May 9, [...]

Published
2024

35. European Commission Approves Merck's KEYTRUDA[R] (pembrolizumab) Plus Padcev[R] (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Subjects
Merck & Company Inc., Seagen Inc., Metastasis -- Care and treatment, Biological products, Antineoplastic agents, Carcinoma -- Care and treatment, Drug approval, Adults, Cancer -- Care and treatment, Antimitotic agents, Business, Business, international, European Union, European Union. European Commission, Padcev (Medication), Keytruda (Medication)
Abstract

Approval of KEYTRUDA plus enfortumab vedotin brings a potential new first-line standard of care to these patients in the European Union RAHWAY, N.J. -- Merck (NYSE: MRK), known as MSD [...]

Published
2024

36. CancerVax Taps Flashpoint Therapeutics' Nanotechnology Platform to Drive Universal Cancer Treatment

Subjects
Biological products industry -- Research agreements, Antineoplastic agents, Cancer -- Care and treatment, Antimitotic agents, Banking, finance and accounting industries, Business
Abstract

Santa Barbara, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Santa Barbara, CA, August 29, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that will [...]

Published
2024

37. Microbiotica's Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies

Subjects
Merck & Company Inc., Medical research, Medicine, Experimental, Ulcerative colitis, Antineoplastic agents, Clinical trials, Melanoma, Pharmaceutical industry, Antimitotic agents, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, United Kingdom, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce [...]

Published
2024

38. Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

Subjects
United States. Food and Drug Administration, Bristol-Myers Squibb Co., Ono Pharmaceutical Company Ltd., Antineoplastic agents, Liver diseases -- Drug therapy, Hepatoma -- Drug therapy, Pharmaceutical industry, Antimitotic agents, Business, Business, international, Yervoy (Medication), Opdivo (Medication)
Abstract

Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator's choice of lenvatinib or sorafenib in this patient population [...]

Published
2024

39. Multiple Myeloma Pipeline Outlook 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics

Subjects
Business -- Research, Antineoplastic agents, Biotechnology, Multiple myeloma, Antimitotic agents, Business, Business, international
Abstract

M2 PRESSWIRE-August 7, 2024-: Multiple Myeloma Pipeline Outlook 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics (C)1994-2024 M2 COMMUNICATIONS RDATE:06082024 DelveInsight's, 'Multiple Myeloma Pipeline Insights 2024' [...]

Published
2024

40. FDA Grants Thermo Fisher Scientific SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Subjects
United States. Food and Drug Administration, Thermo Fisher Scientific Inc., Scientific equipment and supplies industry, T cells, Antineoplastic agents, HLA histocompatibility antigens, Histocompatibility antigens, Antimitotic agents, Business, Business, international
Abstract

WEST HILLS, Calif. -- Thermo Fisher Scientific Inc., the world leader in serving science, today announced that itsSeCore[TM] CDx HLA A Sequencing System has been granted 510(k) clearance by the [...]

Published
2024

41. FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

Subjects
United States. Food and Drug Administration, Antineoplastic agents, Orphan drugs, Antimitotic agents, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the 'Company') (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]

Published
2024

42. Elevar Therapeutics Granted Orphan Medicinal Product Designation by the European Medicines Agency for First-Line Systemic Therapy for Unresectable Hepatocellular Carcinoma

Subjects
Antineoplastic agents, Cancer -- Care and treatment, Liver, Hepatoma -- Care and treatment, Antimitotic agents, Banking, finance and accounting industries, Business
Abstract

FORT LEE, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the European Medicines Agency (EMA) granted Orphan Medicinal Product [...]

Published
2024

43. Merck Receives Positive EU CHMP Opinion for KEYTRUDA[R] (pembrolizumab) Plus Padcev[R] (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Subjects
Merck & Company Inc., Seagen Inc., Metastasis -- Care and treatment, Biological products, Antineoplastic agents, Biotechnology industry, Cancer -- Care and treatment, Pharmaceutical industry, Antimitotic agents, Business, Business, international, European Union, Padcev (Medication), Keytruda (Medication)
Abstract

Opinion granted based on positive overall survival and progression-free survival results from the Phase 3 KEYNOTE-A39 trial Positive opinion marks step forward for a potential new first-line standard of care [...]

Published
2024

44. Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Subjects
Ono Pharmaceutical Company Ltd., Antineoplastic agents, Drugs, Liver diseases -- Care and treatment, Hepatoma -- Care and treatment, Antimitotic agents, Business, Business, international, Yervoy (Medication), Opdivo (Medication)
Abstract

The Application is based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator's choice of lenvatinib or sorafenib in this patient population [...]

Published
2024

45. Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Subjects
Metastasis -- Development and progression -- Drug therapy, Antineoplastic agents, Liver, Hepatoma -- Development and progression -- Drug therapy, Antimitotic agents, Banking, finance and accounting industries, Business
Abstract

SHANGHAI, July 17, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization [...]

Published
2024

46. Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Subjects
Danaher Corp., Antineoplastic agents, Cancer -- Diagnosis, School construction, Drugs -- Product/Service Evaluations, Optical instruments, Antimitotic agents, Business, News, opinion and commentary, Stanford University
Abstract

Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures [...]

Published
2024

47. AstraZeneca to build cancer drugs factory in Singapore

Subjects
AstraZeneca PLC -- Buildings and facilities, Antineoplastic agents, Biological products, Chemotherapy, Cancer -- Chemotherapy, Pharmaceutical industry -- Buildings and facilities, Antimitotic agents, Business, General interest
Abstract

Byline: PHARMACEUTICALS Daniel O'Boyle ASTRAZENECA will build a $1.5 billion (PS1.2 billion) factory in Singapore to make so-called 'biological missiles' that kill cancer cells, the pharma giant revealed today. The [...]

Published
2024

49. eFFECTOR Therapeutics Inc R&D Day - Final

Subjects
Antineoplastic agents, Antimitotic agents, Business
Abstract

Presentation OPERATOR: Good afternoon, and thank you for joining the eFFECTOR investor event. (Operator Instructions) As a reminder, this event is being recorded and a replay will be made available [...]

Published
2024

50. Merck: FDA approves Keytruda in combination with gemcitabine and cisplatin

Subjects
United States. Food and Drug Administration, Merck & Company Inc., Antineoplastic agents, Chemotherapy, Drug approval, Cancer -- Chemotherapy, Pharmaceutical industry, Antimitotic agents, Business, News, opinion and commentary, Keytruda (Medication)
Abstract

Merck announced that the U.S. FDA has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results